Multiple Myeloma: Heterogeneous in Every Way

Abstract excerpt

Multiple myeloma (MM) is a hematological malignancy characterized by the accumulation of tumor plasma cells (PCs) in the bone marrow (BM). Despite considerable advances in terms of treatment, patients' prognosis is still very heterogeneous. Cytogenetics and minimal residual disease both have a major impact on prognosis. However, they do not explain all the heterogeneity seen in the outcomes. Their limitations are...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Multiple Myeloma Research and Treatments
• Share to Peptidase Inhibition and Analysis
• Share to Protein Degradation and Inhibitors